Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, ...

Hedy Lee Kindler, MD, shares new mesothelioma guidelines that have been released by the American Society of Clinical Oncology. In recent years, mesothelioma has shed its prefix as malignant ...

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a first-in-human trial. A first-in-human study (NCT06672185) evaluating ARC101 for the ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY agreed to acquire 2seventy bio, Inc TSVT. Meanwhile, other pipeline and ...

The study achieved its primary endpoint in the estrogen receptor 1-mutant (ESR1m) patient population. This company is expected to post quarterly loss of $0.85 per share in its upcoming report ...

On Tuesday, based on data from those with estrogen receptor 1 (ESR1m) mutations, the duo said that the protein degrader reached the primary endpoint in their Phase 3 VERITAC-2 trial designed to ...